In Vitro Diagnostics (IVD) include reagents, instruments, and systems intended for use in the diagnosis of disease or other conditions, including the determination of the state of health, in order to treat or prevent disease. The reagents, instruments and systems are intended for use in the collection, preparation, and examination of specimens taken from the human body. The categories tracked under this market are Cardiac Disease, Hematological Disorders, Hormonal Disorders, Metabolic Disorder, Infectious Disease, IVD Analyzers and Reagents, Oncology and Reproductive Health Diagnostics. Cytomegalovirus (CMV) tests are used for the detection of CMV, which can cause serious illness in immunocompromised patients, and infants, with up to 1 in 3 children being infected and over half of adults by the age of 40 in the United States. GlobalData uses proprietary data and analytics to provide a comprehensive report on the cytomegalovirus (cmv) tests market in Norway. Buy the latest report here.

In 2022, GlobalData’s Market Model methodology determined that the leading player in the cytomegalovirus (cmv) tests market in Norway was Abbott Laboratories followed by Altona Diagnostic, bioMerieux, Bio-Rad Laboratories, Danaher, DiaSorin, F. Hoffmann-La Roche, Immucor, Luminex, MBL International, Merck, Qiagen, Quidelortho, Siemens, StatLab Medical (SLMP) and Trinity Biotech.

Understanding market size can be crucial to evaluate opportunities and make informed decisions about market entry and exit. Medical device companies can identify attractive segments in respective markets as well as develop marketing strategies based on forecasts for those segments.

CMV infections are most prevalent in pregnant women, immunocompromised patients, and infants. CMV testing is usually performed with the help of Enzyme Immuno Assay (EIA) Tests, Nucleic Acid Amplification Tests (NAATs), and other tests. The tests carried out in laboratories are considered. The CMV Test market includes the sub-segments Cytomegalovirus (CMV) Enzyme Immuno Assay/Enzyme Linked Immunosorbent Assay (EIA/ELISA) Tests, Cytomegalovirus (CMV) Nucleic Acid Amplification Tests (NAATs), and Other Cytomegalovirus (CMV) Tests.

The cytomegalovirus (cmv) tests market in Norway can expand or contract due to a variety of reasons including population demographics, disease incidence and prevalence, macroeconomic issues, and geopolitical considerations. Disruption to a market could be caused by a sudden, unexpected change in these factors, but it could also be driven by changes in clinical practice, leading to a change in diagnosis or treatment of patients, as part of a process to generally improve medical practice.

For the latest analysis of the market size cytomegalovirus (cmv) tests in Norway, buy the report here.

This content was updated on 27 May 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Medical Intelligence Center Market Models are the gold standard of medical device market valuation, company share estimation and market trend forecasting. GlobalData uses a patient-based forecast model or installed base methodology to determine the market size for therapeutic indications and capital equipment expenditures. Estimates are based on a number of sources, including primary research—KOL and industry contact interviews—and secondary research, such as company reports, press releases, published articles, proprietary databases, and general news media.